BG105127A - Метод за лечение - Google Patents

Метод за лечение

Info

Publication number
BG105127A
BG105127A BG105127A BG10512701A BG105127A BG 105127 A BG105127 A BG 105127A BG 105127 A BG105127 A BG 105127A BG 10512701 A BG10512701 A BG 10512701A BG 105127 A BG105127 A BG 105127A
Authority
BG
Bulgaria
Prior art keywords
treament
nicotine addiction
smoking
paroxetine
solvate
Prior art date
Application number
BG105127A
Other languages
English (en)
Inventor
Martin Steiner
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of BG105127A publication Critical patent/BG105127A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретението се отнася до метод за намаляване или спиране на тютюнопушенето, или за предотвратяване на повторно привикване. По метода се прилага нетоксично количество пароксетин или негова фармацевтично приемлива сол или солват.
BG105127A 1998-06-16 2001-01-08 Метод за лечение BG105127A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9812941.4A GB9812941D0 (en) 1998-06-16 1998-06-16 Method of treatment
PCT/US1999/013623 WO1999065491A1 (en) 1998-06-16 1999-06-16 Method of treatment

Publications (1)

Publication Number Publication Date
BG105127A true BG105127A (bg) 2001-11-30

Family

ID=10833832

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105127A BG105127A (bg) 1998-06-16 2001-01-08 Метод за лечение

Country Status (20)

Country Link
EP (1) EP1087766A4 (bg)
JP (1) JP2002518330A (bg)
KR (1) KR20010052895A (bg)
CN (1) CN1305379A (bg)
AP (1) AP2000002002A0 (bg)
AU (1) AU740749B2 (bg)
BG (1) BG105127A (bg)
BR (1) BR9911150A (bg)
CA (1) CA2335236A1 (bg)
CZ (1) CZ20004698A3 (bg)
EA (1) EA003584B1 (bg)
GB (1) GB9812941D0 (bg)
HU (1) HUP0102507A3 (bg)
IL (1) IL139943A0 (bg)
NO (1) NO20006383D0 (bg)
NZ (1) NZ508532A (bg)
PL (1) PL345261A1 (bg)
SK (1) SK19192000A3 (bg)
WO (1) WO1999065491A1 (bg)
ZA (1) ZA200007396B (bg)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2418038A1 (en) * 2000-08-28 2002-03-07 Synthon B.V. Paroxetine compositions and processes for making the same
IL162666A0 (en) 2001-12-28 2005-11-20 Teva Pharma A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
FR2926221A1 (fr) * 2008-01-14 2009-07-17 Tassin Thomas Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
KR930702000A (ko) * 1990-11-24 1993-09-08 데이빗 로버츠 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method

Also Published As

Publication number Publication date
WO1999065491A1 (en) 1999-12-23
EP1087766A1 (en) 2001-04-04
IL139943A0 (en) 2002-02-10
CA2335236A1 (en) 1999-12-23
JP2002518330A (ja) 2002-06-25
EP1087766A4 (en) 2001-11-21
HUP0102507A2 (hu) 2002-05-29
CN1305379A (zh) 2001-07-25
EA003584B1 (ru) 2003-06-26
PL345261A1 (en) 2001-12-03
NZ508532A (en) 2003-08-29
SK19192000A3 (sk) 2001-05-10
EA200100041A1 (ru) 2001-06-25
ZA200007396B (en) 2002-02-27
AU740749B2 (en) 2001-11-15
NO20006383L (no) 2000-12-14
AU4688599A (en) 2000-01-05
GB9812941D0 (en) 1998-08-12
HUP0102507A3 (en) 2003-12-29
BR9911150A (pt) 2001-03-06
AP2000002002A0 (en) 2000-12-31
CZ20004698A3 (cs) 2002-02-13
KR20010052895A (ko) 2001-06-25
NO20006383D0 (no) 2000-12-14

Similar Documents

Publication Publication Date Title
FI960324L (fi) Parannettu nikotiinipastilli ja terapeuttinen menetelmä tupakoinnin lopettamiseksi
BG105459A (bg) Фармацевтична форма съдържаща моксифлоксацин
WO2000016762A3 (en) Method for reducing nicotine dependency
AUPN603895A0 (en) Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
ZA977783B (en) Method of inhibiting fibrosis with a somatostatin agonist
HUP0103877A2 (hu) Arilcsoporttal szubsztituált propanolaminszármazékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
WO2000021515A3 (en) Intranasal codeine for the rapid suppression of cough and rapid relief of pain
IL206830A (en) Use of an integrin-containing antagonist of the alpha 1 subunit - of the integrin to prepare a drug for the treatment of osteoporosis
BG105534A (bg) 5ht1 средство и метод за лечение на мигрена
PT998287E (pt) Utilizacao de levobupivacaina
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
ZA200004406B (en) Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal.
MY121623A (en) Methods of preventing breast cancer.
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
BG105127A (bg) Метод за лечение
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
NO20012226L (no) Terapeutiske midler for medikamentavhengighet
IL126158A0 (en) Method for treating substance abuse
WO2002007733A3 (en) Method for enhancing bone mineral density gain by administration of raloxifene
BRPI0410173A (pt) composição farmacêutica para a prevenção e tratamento da viciação em nicotina em um mamìfero
AU6195998A (en) Improved nicotine lozenge and therapeutic method for smoking cessation
AU9235101A (en) Remedies for retinal nerve diseases containing 1,2-ethanediol derivatives or salts thereof
PL346342A1 (en) The use of r(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders